Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

According to Cancer Research UK, there are around 6,600 new liver cancer cases in the UK every year, and around 5,830 people ...

【导读】肝细胞癌（HCC）中肿瘤内免疫浸润在与肿瘤细胞的相互作用中起着关键作用。然而，其表型和相关空间结构尚未明确。11月7日，中国医学科学院与北京协和医院研究人员合作共同在期刊《Cell Death&Disease》上发表了题为“DKK1+ ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

Liver cancer is the sixth leading cause of cancer death in the U.S. The most common type of liver cancer in adults is ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

Chemoembolization (TACE): Delivers chemotherapy directly into the liver Thermal ablation: Utilizing heat to destroy cancer cells Get Vaccinated: Protect yourself with the hepatitis B vaccine ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

[1]Peng Zhou, Wen-yi Chang, De-ao Gong, Jie Xia, Wei Chen, Lu-yi Huang, Rui Liu, Yi Liu, Chang Chen, Kai Wang, Ni Tang, Ai-long Huang. High dietary fructose promotes hepatocellular carcinoma ...